Callio Therapeutics Doses First Patient in Global Phase I Trial of Dual-Payload HER2 ADC CLIO-8221

New updates have been reported about Callio Therapeutics.

Callio Therapeutics has advanced its lead dual-payload antibody-drug conjugate, CLIO-8221, into the clinic, dosing the first patient in a Phase I study for advanced HER2-expressing solid tumors in Australia. The trial, which has U.S. FDA IND clearance and is planned for expansion into China pending review by the NMPA, marks the company’s transition to a clinical-stage biotherapeutics player with a global development footprint.

CLIO-8221 is designed as a first-in-class HER2-targeted ADC that combines a topoisomerase 1 inhibitor with an ATR inhibitor, aiming to address resistance mechanisms that limit the durability of existing single-payload HER2 ADCs. Callio reports that preclinical data showed strong tumor regression, including in models insensitive or refractory to Topo1 inhibitors, and suggests a broader therapeutic window supported by its proprietary linker platform intended to reduce systemic toxicity.

Management emphasizes that CLIO-8221 is the first program from its dual-payload pipeline to reach the clinic, achieved roughly one year after the company’s launch, underscoring the speed and scalability of its modular ADC platform. The company believes that simultaneous targeting of DNA replication stress and the DNA damage response could generate deeper and more durable responses in patients whose cancers progress despite continued HER2 expression.

Strategically, Callio is positioning its technology to capture share in the growing market for next-generation ADCs by focusing on hard-to-treat tumors and overcoming payload resistance observed with approved HER2-directed therapies. The ongoing Phase I trial in Australia and the U.S., with anticipated Chinese sites, should generate early safety, tolerability, and preliminary efficacy data that will guide dose selection, expansion cohorts, and partnering or financing options.

Headquartered in Seattle and Singapore and backed by specialist life science investors, Callio is building a broader pipeline of dual-payload ADCs with rationally paired payloads beyond CLIO-8221. Near-term value inflection points include initial readouts from the Phase I program and movement of additional candidates into clinical testing, which will be critical for validating the platform, informing future capital needs, and shaping strategic discussions with potential collaborators and commercial partners.